SLC5A2 and chronic kidney disease: In large clinical trials such as DAPA-CKD and EMPA-KIDNEY, SGLT-2 inhibitors significantly reduced heart failure-related hospitalization rates and the risk of cardiovascular death in non-diabetic CKD patients.